TELA Bio (TELA) Set to Announce Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is expected to be issuing its Q3 2026 resultson Tuesday, November 10th. Analysts expect TELA Bio to announce earnings of ($0.19) per share and revenue of $20.00 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last released its earnings results on Monday, August 10th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%. The business had revenue of $19.29 million for the quarter, compared to the consensus estimate of $20.01 million. On average, analysts expect TELA Bio to post ($0.76) EPS for the current fiscal year and ($0.44) EPS for the next fiscal year.

TELA Bio Stock Performance

Shares of TELA opened at $0.82 on Monday. TELA Bio has a 52-week low of $0.50 and a 52-week high of $1.50. The business’s fifty day moving average is $1.02 and its 200-day moving average is $0.85. The firm has a market cap of $37.02 million, a price-to-earnings ratio of -1.06 and a beta of 1.46.

Insider Buying and Selling at TELA Bio

In other news, Director Joseph Capper acquired 25,000 shares of the stock in a transaction dated Thursday, September 17th. The stock was bought at an average price of $1.22 per share, with a total value of $30,500.00. Following the completion of the purchase, the director directly owned 179,827 shares of the company’s stock, valued at $219,388.94. This represents a 16.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 115,000 shares of company stock worth $119,500 in the last quarter. Insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TELA shares. UBS Group set a $2.00 price objective on TELA Bio in a research report on Friday, September 25th. Wall Street Zen raised TELA Bio to a “sell” rating in a research note on Saturday, October 31st. Craig Hallum assumed coverage on TELA Bio in a research report on Friday, September 25th. They issued a “buy” rating and a $2.00 target price on the stock. Finally, Weiss Ratings raised TELA Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, TELA Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $2.14.

TELA Bio Company Profile

TELA Bio, Inc is a medical technology company that develops and commercializes advanced tissue-reinforcement products for soft-tissue repair and reconstruction. The company’s products are designed to support the repair of damaged or weakened tissue while preserving a more natural tissue response.

TELA Bio’s principal product platform is OviTex Reinforced Tissue Matrix, which combines biologic tissue with polymer reinforcement in a proprietary, textile-like design. OviTex products are used in procedures involving hernia and abdominal wall repair, as well as other soft-tissue reconstruction applications.